NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $209.73 +3.49 (+1.69%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$207.50 -2.23 (-1.06%) As of 06/26/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quest Diagnostics Stock (NYSE:DGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$206.55▼$209.8950-Day Range$186.52▼$209.7352-Week Range$164.65▼$213.50Volume1.35 million shsAverage Volume841,198 shsMarket Capitalization$23.22 billionP/E Ratio23.17Dividend Yield1.64%Price Target$216.58Consensus RatingModerate Buy Company Overview Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening. Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology. Quest also offers specialized esoteric testing, employer and occupational health testing, clinical trial laboratory services and health information solutions designed to integrate lab data into provider and population health workflows. These capabilities are delivered through laboratory infrastructure, patient collection sites and digital tools that enable ordering, reporting and analytics. Quest primarily serves the United States healthcare market—providing testing and related services to physician practices, hospitals, payers, employers and governmental agencies—while maintaining capabilities that support international clinical trials and diagnostics initiatives. The company has operated for multiple decades and is structured with centralized laboratory operations, regional service locations and an executive leadership team responsible for strategic, clinical and operational oversight.AI Generated. May Contain Errors. Read More Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreDGX MarketRank™: Quest Diagnostics scored higher than 93% of companies evaluated by MarketBeat, and ranked 38th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 7 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageQuest Diagnostics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.93% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 7.93% in the coming year, from $10.72 to $11.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 23.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 23.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.76.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.46. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Quest Diagnostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.12% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 4.26.Change versus previous monthShort interest in Quest Diagnostics has recently decreased by 0.33%, indicating that investor sentiment is improving. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.67%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 38.01%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 29.73% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. News and Social Media4.4 / 5News Sentiment1.05 News SentimentQuest Diagnostics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Quest Diagnostics this week, compared to 7 articles on an average week.Search Interest8 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows5 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,570,800.00 in company stock.Percentage Held by Insiders0.88% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DGX Stock News HeadlinesQuest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gainsJune 26 at 12:30 AM | marketwatch.comQuest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into PsychiatryJune 26 at 9:27 AM | finance.yahoo.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.June 27 at 1:00 AM | Porter & Company (Ad)Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease TestingJune 24 at 12:21 AM | uk.finance.yahoo.comQuest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease TestingJune 24 at 9:05 AM | prnewswire.comIs Quest Diagnostics Stock Underperforming the S&P 500?June 20, 2026 | finance.yahoo.comQuest Diagnostics (NYSE:DGX) Upgraded at Wall Street ZenJune 20, 2026 | americanbankingnews.comInsider Selling: Quest Diagnostics (NYSE:DGX) CEO Sells 10,000 Shares of StockJune 3, 2026 | insidertrades.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $173.47 at the beginning of 2026. Since then, DGX stock has increased by 20.9% and is now trading at $209.7260. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) released its earnings results on Tuesday, April, 21st. The medical research company reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.37 by $0.13. The firm's revenue for the quarter was up 9.2% on a year-over-year basis. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' Board of Directors initiated a stock buyback program on Tuesday, February 10th 2026, which authorizes the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.7% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's leadership believes its shares are undervalued. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include these companies: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an initial public offering on Tuesday, January 7th 2025. The company issued 2,300,000 shares at $4.00-$6.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Quest Diagnostics' top institutional investors include EdgePoint Investment Group Inc. (2.03%), Dimensional Fund Advisors LP (1.76%), Bank of America Corp DE (1.58%) and Bank of New York Mellon Corp (0.59%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Record date for 4/20 Dividend4/06/2026Ex-Dividend for 4/20 Dividend4/06/2026Dividend Payable4/20/2026Last Earnings4/21/2026Today6/27/2026Record date for 7/22 Dividend7/08/2026Ex-Dividend for 7/22 Dividend7/08/2026Dividend Payable7/22/2026Next Earnings (Estimated)7/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 DGX's financial health is in the Green zone, according to TradeSmith. DGX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryHealth Care Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees57,000Year Founded1967Price Target and Rating Average Price Target for Quest Diagnostics$216.58 High Price Target$235.00 Low Price Target$178.00 Potential Upside/Downside+3.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$9.05 Trailing P/E Ratio23.17 Forward P/E Ratio19.56 P/E Growth2.46Net Income$992 million Net Margins9.07% Pretax Margin12.20% Return on Equity15.60% Return on Assets7.06% Debt Debt-to-Equity Ratio0.67 Current Ratio1.18 Quick Ratio1.08 Sales & Book Value Annual Sales$11.04 billion Price / Sales2.10 Cash Flow$15.43 per share Price / Cash Flow13.59 Book Value$64.78 per share Price / Book3.24Miscellaneous Outstanding Shares110,700,000Free Float109,722,000Market Cap$23.22 billion OptionableOptionable Beta0.59 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:DGX) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
